Clinical significance of striatal DOPA decarboxylase activity in Parkinson's disease

Journal of Nuclear Medicine

Volumn 37, Issue 2, 1996, Pages 216-222

  Ishikawa, Tatsuya ^a   Dhawan, Vijay ^a   Chaly, Thomas ^a   Margouleff, Claude ^a   Robeson, William ^a   Robert Dahl, J ^a   Mandel, Francine ^a   Spetsieris, Phoebe ^a   Eidelberg, David ^a  

^a NORTH SHORE UNIVERSITY HOSPITAL   (United States)

Author keywords

DOPA decarboxylase activity; parkinsonism; PET

Indexed keywords

6 FLUORODOPA F 18; AROMATIC LEVO AMINO ACID DECARBOXYLASE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMPARTMENT MODEL; CONTROLLED STUDY; CORPUS STRIATUM; DRUG UPTAKE; FEMALE; HUMAN; MALE; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

BRAIN; CASE-CONTROL STUDIES; CORPUS STRIATUM; DIHYDROXYPHENYLALANINE; DOPA DECARBOXYLASE; FEMALE; FLUORINE RADIOISOTOPES; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PARKINSON DISEASE; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0029873012     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Garnett E, Nahmias C, Firnau G. Central dopammergic pathways in hemiparkinsonism examined by positron emission tomography. Can J Neurol Sci 1984;11.174-179.
2. Leenders KL, Palmer AJ, Quinn N, et al Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography. J Neurol Neurosurg Psychiatry 1986,49:853-860.
3. Patlak CS, Blasberg RG, Fenstermacher JD. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data J Cereb Blood Flow Metab 1983;3:1-7.
4. Martin WRW, Palmer MR, Patlak CS, Calne DB. Nigrostriatal function in humans studied with positron emission tomography. Ann Neurol 1989;26:535-542.
5. 18F-fluorodopa positron emission tomography studies. Movement Disorders 1990,5:203-351
6. Leenders KL, Salmon EP, Tyrrell P, et al. The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease. Arch Neurol 1990,47:1290-1298
7. 18F-Dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Ann Neurol 1990,28:547-555.
8. Sawle GV, Colebatch JG, Shah A, Brooks DJ, Marsden CD, Frackowiak SJ. Striatal function in normal aging implications for Parkinson's disease. Ann Neurol 1990;28: 799-804
9. Gjedde A, Reith J, Dyve S, et al. Dopa decarboxylase activity of the living human brain. Proc Natl Acad Sci 1991;88:2721-1725.
10. 18F]fluoro-L-dopa in rat. J Cereb Blood Flow Metab 1990;10 707-719
11. 18F]fluoro-DOPA and positron emission tomography: error analysis and application to normal subjects. J Cereb Blood Flow Metab 1993;13:43-56.
12. 18F]Fluoro-DOPA in human positron emission tomographic study. J Cereb Blood Flow Metab 1991,11: 898-913.
13. Dhawan V, Ishikawa T, Patlak C, et al. Combined FDOPA and 3OMFD PET studies in Parkinson's disease. J Nucl Med 1996,37:209-216.
14. 18F]fluoro-L-DOPA in the rhesus monkey brain. J Cereb Blood Flow Metab 1991;11:726-734.
15. 18F]6-fluoro-3-O-methyl-L-dopa in the human brain J Cereb Blood Flow Metab 1994,14:664-670.
16. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:21-25.
17. 18F-DOPA uptake: absence of an aging effect. J Cereb Blood Flow Metab 1993, 13 881-888
18. Wahl LM, Garnett ES, Chirakai R, et al Quantification of dopamine metabolism in man: what is the most justifiable approach? J Cereb Blood Flow Metab 1993;13.(suppl 1)S722.
19. Anderson TW. An Introduction to Multivariate Statistical Analysis. New York: John Wiley & Sons, 1984.
20. Fahn S, Elton RL, the UPDRS Development Committee. Unified Parkinson disease rating scale. In: Fahn S, Marsden CD, Calne D, Goldstein M. eds. Recent developments in Parkinson's disease, vol 2 Floral Park, NJ: Macmillan; 1987:293-304
21. 3H]L-DOPA in rats Biochem Pharmacol 1990,39:1853-1860.
22. Oldendorf WH, Szabo J. Amino acid assignment to one of three blood-brain barrier amino acid carriers. Am J Physiol 1976,230:94-98
23. 11C]Armnocyclohexane-carboxylate for the measurement of amino acid uptake and distribution volume in human brain. J Cereb Blood Flow Metab 1990;10.727-739
24. Takikawa S, Dhawan V, Chaly T, et al. Input functions for 6-[fluonne-18]fluorodopa quantitation in parkinsonism comparative studies and clinical correlations J Nucl Med 1994,35.955-963
25. 18F]fluoro-L-Dopa metabolism in living human brain: a comparison of six analytical methods. J Cereb Blood Flow Metab 1993,13:57-69.
26. Bemheimer H, Birkmayer W, Hornykiewicz O, et al Brain dopamine and the syndromes of Parkinson and Huntington. J Neurol Sci 1973,20:415-455.
27. 18F]fluorodopa studies correlate with dopamine cell counts and leveis. Ann Neurol 1993;34:324-330.
28. Letters to the editor. An aging effect in striatal fluorodopa uptake? Large versus small ROJs J Cereb Blood Flow Metab 1994,14:882-883
29. Martin WRW, Palmer MR, Patlak CS, et al. Nigrostriatal function in man studied with positron emission tomography. Ann Neurol 1989;26:535-542.
30. Vingerhoets FJG, Snow BJ, Sculzer M, et al. Reproducibility of fluorine-18-6-fluorodopa positron emission tomography in normal human subjects J Nucl Med 1994 35 18-23.
31. Murase K, Kuwabara H, Cumming P, et al. Relative activity of dopa decarboxylase remained unchanged with age J Nucl Med 1994 5(suppl):10P.
32. Kish SJ, Zhong XH, Hornykiewcz O, Haycock JW. Striatal 3,4,dihydroxyphenylalanine decarboxylase in aging disparity between postmortem and positron emission tomography studies? Ann Neurol 1995,38 260-264.